Delivery Order SPE2DB22D2211-SPE2DB24FMTB1
- Not listed
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a for-profit subsidiary of Amerisourcebergen Corporation, to provide Ondansetron HCl 8 mg tablets. The $4,310.25 contract has a completion date of February 23, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 2025, which serves as the primary vehicle for the company to deliver pharmaceuticals and...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract valued at $1,734.42 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Ondansetron ODT 8 mg tablets. The contract has a completion date of January 26, 2024 and was awarded on January 25, 2024. Amerisourcebergen Drug Corp is the prime contractor and does not have any major subcontractors listed. This delivery order is...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of Ondansetron HCL 8 mg tablets. The $2,780.75 contract has a completion date of February 2, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen with a potential...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply 4,563,728,753 units of Ondansetron ODT 8 mg tablets. The $3,297.64 contract has a completion date of February 22, 2024. Amerisourcebergen Drug Corp is the prime contractor and no set-aside designation was used. This delivery order is issued under an indefinite delivery contract (IDC) valued up...
- The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, through its Corporate Office division, a firm fixed price delivery order contract worth $1,222.69 for the supply of 4,564,095,638 units of Ondansetron HCL 4 MG tablets. The contract has an ultimate completion date of March 28, 2024. Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical sourcing and distribution company Amerisourcebergen Corporation, is the prime contractor. This delivery order is part...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply Ondansetron HCL 4 mg tablets. The $1,667.12 contract has a completion date of February 6, 2024. Amerisourcebergen Drug Corp is the prime contractor and there are no set-aside designations indicated. This delivery order is issued under a larger indefinite delivery contract (IDC) with a potential...
- The Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,643,171 units of Ondansetron ODT 8 mg tablets in 30-count packages. The $2,239.95 contract has a completion date of February 14, 2024 and was awarded on February 13, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation for this award. This delivery order is part of a...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,563,649,459 units of Ondansetron HCL 8 mg tablets. The $1,839.70 order has a completion date of February 14, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4 mg ondansetron hydrochloride tablets in 30-count packages. The $2,436.56 contract has a performance period ending on March 21, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Ondansetron HCL 4 mg tablets. The contract has a potential value of $1,744.81 and a period of performance through March 5, 2024. Amerisourcebergen Drug Corp is the prime contractor and there are no set-aside designations. The company also holds an indefinite delivery contract (IDC) with DLA Troop...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB24FMTB1Delivery Order
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of Ondansetron HCL 8 mg tablets in 30-count packages. The contract has a potential value of $29,504.32 and a completion date of February 5, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as the prime contractor supplying pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. This delivery order is issued under an indefinite delivery contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA, which serves as the primary contract vehicle for delivering a comprehensive range of medications and healthcare materials to military treatment programs and medical facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.5k | 2/2/24 |